Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-06-28 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation regarding loss of share certificate.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) regarding an intimation under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015. It details the loss of share certificates and a request for stop transfer. The content is a regulatory notification related to share certificate handling and does not contain financial statements, management discussion, or report publication. The document length is short (1936 characters) and is a formal regulatory communication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-28 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product by Lupin Limited following FDA approval. It is addressed to stock exchanges under SEBI regulations, indicating a regulatory disclosure. The content focuses on the product launch and company information, without any financial data, detailed financial results, or management discussion. The document length is 3574 characters, which is relatively short and typical for a press release. It does not contain financial statements or detailed analysis, nor does it announce voting results, board changes, or legal proceedings. It is not an earnings release or an investor presentation. The document is a regulatory announcement about a business development event (product launch) and is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2021-06-25 English
Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the United States.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a pharmaceutical product by Lupin Limited, including details about FDA approval and product information. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch and regulatory approval, not a financial report, earnings release, or management discussion. It does not contain financial statements, voting results, or regulatory filings beyond the disclosure of a business event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories. The document length is under 5,000 characters and is a standalone announcement, not a report or presentation.
2021-06-25 English
ESOP/ESOS/ESPS
Regulatory Filings Classification · 90% confidence The document contains only placeholders for images and no textual content or financial data. It is extremely short (189 characters) and does not contain any report, announcement, or detailed information. Given the lack of content, it cannot be classified as any specific report type. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings without substantive content.
2021-06-22 English
Allotment of 131894 fully paid-up equity shares of Rs. 2/- each upon exercising of options granted to the employees under Stock option plans of the Company.
Share Issue/Capital Change Classification · 95% confidence The document is a letter addressed to BSE Limited disclosing the allotment of shares under the company's Employee Stock Option Plan (ESOP). It mentions the allotment of fully paid-up equity shares and the resulting increase in the company's issued and paid-up capital. The document is short (1250 characters) and is a regulatory disclosure pursuant to SEBI Listing Obligations and Disclosure Requirements, specifically about share allotment under ESOP. This fits the category of Share Issue/Capital Change announcements rather than a full report or financial statement. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2021-06-22 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of U.S. FDA approval for a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or management discussion. The document length is 3975 characters, which is relatively short and consistent with a press release or regulatory announcement. There is no financial data, no meeting materials, no voting results, no audit information, no legal proceedings, no capital changes, and no executive compensation details. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and disclosures that do not fit other specific categories.
2021-06-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.